Biodexa Pharmaceuticals (BDRX) Goodwill & Intangibles (2013 - 2025)

Biodexa Pharmaceuticals has reported Goodwill & Intangibles for 13 years, with the latest figure at $7.5 million in Q4 2025.

• Quarterly Goodwill & Intangibles rose 3.62% year-over-year to $7.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.5 million (up 3.62% YoY) and the FY2025 annual result came in at $7.4 million, up 2.71% from the prior year.
• Goodwill & Intangibles was little changed at $7.5 million in Q4 2025 per BDRX's latest filing, from $7.5 million in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $21.1 million in Q4 2021 and troughed at $6256.8 in Q2 2023.
• A 5-year average of $8.3 million and a median of $7.5 million in 2025 frame the typical range for Goodwill & Intangibles.
• The sharpest annual moves came in 2023 and 2024: Goodwill & Intangibles sank 99.5% in 2023, then surged 121102.58% in 2024.
• Over 5 years, Goodwill & Intangibles stood at $21.1 million in 2021, then declined by 12.38% to $18.5 million in 2022, then tumbled by 80.28% to $3.7 million in 2023, then soared by 98.53% to $7.2 million in 2024, then gained by 3.62% to $7.5 million in 2025.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $7.5 million, $7.5 million, and $7.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.